Ron Tintner

Ron Tintner, MD

Associate Professor of Clinical Neurology, Academic Institute
Associate Clinical Member, Research Institute
Houston Methodist
Weill Cornell Medical College


Ron Tintner, M.D. received his training in internal medicine and neurology at the University of Texas Southwestern Medical School in Dallas, where he remained on the faculty from 1984 through 1994. While there, he was director of the movement disorders clinic and co-director of the Southwestern Clinic for Alzheimer’s and Related Disorders. He was in the private practice of neurology on the Monterey Peninsula of California till early 2000, and at the Parkinson’s Institute in Sunnyvale, CA through June 2000. He was on the faculty at the Baylor College of Medicine in Houston as a member of the team at the Parkinson’s Disease Center and Movement Disorders Clinic from 2000 until 2005. He joined the department of Neurology at the Methodist Neuroscience Institute in June 2005.

Description of Research

Dr. Tintner’s clinical and research interests include movement disorders (parkinsonism, tremor, Tourette syndrome, dystonia), motor control and cognitive function, and the neurobiology of music.

Areas Of Expertise

Parkinson’s disease Movement disorders Motor control
Education & Training

Residency, University of Texas Southwestern Medical Center
MD, University of Florida
Internship, NewYork-Presbyterian Healthcare System
MS, The University of Massachusetts

Reliability of a new scale for essential tremor
Elble, R, Comella, C, Fahn, S, Hallett, M, Jankovic, J, Juncos, JL, Lewitt, P, Lyons, K, Ondo, WG, Pahwa, R, Sethi, K, Stover, N, Tarsy, D, Testa, C, Tintner, R, Watts, R & Zesiewicz, T 2012, , Movement Disorders, vol. 27, no. 12, pp. 1567-1569.

A pilot clinical trial of creatine and minocycline in early parkinson disease: 18-month results
The NINDS NET-PD Investigators 2008, , Clinical Neuropharmacology, vol. 31, no. 3, pp. 141-150.

Botulinum toxin
Tintner, R & Jankovic, J 2007, . in Clinical Diagnosis and Management of Dystonia. CRC Press, pp. 189-207.

Report from a U.S. conference on essential tremor
Elble, RJ, Watts, R, Sethi, K, Lyons, K, Comella, C, Fahn, S, Hallett, M, Jankovic, J, Juncos, J, Louis, E, Ondo, WG, Pahwa, R, Stern, M, Tanner, C & Tintner, R 2006, , Movement Disorders, vol. 21, no. 12, pp. 2052-2061.

Tremor amplitude is logarithmically related to 4- and 5-point tremor rating scales
Elble, RJ, Pullman, SL, Matsumoto, JY, Raethjen, J, Deuschl, G & Tintner, R 2006, , Brain, vol. 129, no. 10, pp. 2660-2666.

A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease
The NINDS NET-PD Investigators 2006, , Neurology, vol. 66, no. 5, pp. 664-671.

Autonomic function after botulinum toxin type A or B: A double-blind, randomized trial
Tintner, R, Gross, R, Winzer, UF, Smalky, KA & Jankovic, J 2005, , Neurology, vol. 65, no. 5, pp. 765-767.

Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson disease
Tintner, R, Manian, P, Gauthier, P & Jankovic, J 2005, , Archives of neurology, vol. 62, no. 8, pp. 1290-1295.

Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease
Ondo, WG, Tintner, R, Voung, KD, Lai, D & Ringholz, G 2005, , Movement Disorders, vol. 20, no. 8, pp. 958-963.

Striatal deformities of the hand and foot in Parkinson's disease
Ashour, R, Tintner, R & Jankovic, J 2005, , Lancet Neurology, vol. 4, no. 7, pp. 423-431.

Dopamine agonists in Parkinson's disease
Tintner, R & Jankovic, J 2003, , Expert Opinion on Investigational Drugs, vol. 12, no. 11, pp. 1803-1820.

Benefits and risks of pharmacological treatments for essential tremor
Lyons, KE, Pahwa, R, Comella, CL, Eisa, MS, Elble, RJ, Fahn, S, Jankovic, J, Juncos, JL, Koller, WC, Ondo, WG, Sethi, KD, Stern, MB, Tanner, CM, Tintner, R & Watts, RL 2003, , Drug Safety, vol. 26, no. 7, pp. 461-481.

Tetrabenazine treatment for Huntington's disease-associated chorea
Ondo, WG, Tintner, R, Thomas, M & Jankovic, J 2002, , Clinical Neuropharmacology, vol. 25, no. 6, pp. 300-302.

Treatment options for Parkinson's disease
Tintner, R & Jankovic, J 2002, , Current opinion in neurology, vol. 15, no. 4, pp. 467-476.

Intrafamilial phenotypic variability of the DYT1 dystonia: From asymptomatic TOR1A gene carrier status to dystonic storm
Opal, P, Tintner, R, Jankovic, J, Leung, J, Breakefield, XO, Friedman, J & Ozeluis, L 2002, , Movement Disorders, vol. 17, no. 2, pp. 339-345.

Botulinum toxin for the treatment of cervical dystonia
Tintner, R & Jankovic, J 2001, , Expert Opinion on Pharmacotherapy, vol. 2, no. 12, pp. 1985-1994.

Dystonia and parkinsonism
Jankovic, J & Tintner, R 2001, , Parkinsonism and Related Disorders, vol. 8, no. 2, pp. 109-121.

Focal dystonia: the role of botulinum toxin.
Tintner, R & Jankovic, J 2001, , Current Neurology and Neuroscience Reports, vol. 1, no. 4, pp. 337-345.

Acetylcholine receptor antibodies in the Lambert-Eaton myasthenic syndrome
Katz, JS, Wolfe, GI, Bryan, WW, Tintner, R & Barohn, RJ 1998, , Neurology, vol. 50, no. 2, pp. 470-475.

Cognitive Deficits in Asymptomatic First-Degree Relatives of Alzheimer's Disease Patients
Hom, J, Turner, MB, Risser, R, Bonte, FJ & Tintner, R 1994, , Journal of Clinical and Experimental Neuropsychology, vol. 16, no. 4, pp. 568-576.